Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) has increased, indicating a growing interest in investments within this sector, with a total balance of 158.34 billion yuan as of July 1, reflecting a continuous increase over the past seven trading days [1]. Financing Balance - As of July 1, the total financing balance on the STAR Market reached 157.77 billion yuan, an increase of 6.26 million yuan from the previous trading day [1]. - The stock with the highest financing balance is SMIC, with a latest balance of 7.12 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.50 billion yuan and 3.65 billion yuan respectively [1]. - A total of 315 stocks saw an increase in financing balance, while 269 stocks experienced a decrease [1]. - Notable increases in financing balance were observed in Xiangyu Medical (66.24%), Botao Bio (43.29%), and Nanmo Bio (31.08%) [1]. Securities Lending Balance - The total securities lending balance on the STAR Market reached 5.65 billion yuan, with an increase of 8.89 million yuan from the previous trading day [1]. - SMIC also leads in securities lending balance with 20 million yuan, followed by Haiguang Information and Chipone Technology, both at 16 million yuan [2]. - A total of 137 stocks saw an increase in securities lending balance, while 133 stocks experienced a decrease [2]. - Significant increases in securities lending balance were noted for Diao Micro (59.14%), Huahai Qingke (56.71%), and China Shipbuilding Gas (53.60%) [2].

Market Overview - On July 1, the Shanghai Composite Index rose by 0.39%, with the total margin trading balance reaching 1,854.563 billion yuan, an increase of 4.111 billion yuan from the previous trading day [1] - The margin trading balance in the Shanghai market was 935.827 billion yuan, up by 1.786 billion yuan; in the Shenzhen market, it was 912.867 billion yuan, an increase of 2.269 billion yuan; and in the Beijing Stock Exchange, it was 5.869 billion yuan, up by 0.055 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 20 sectors saw an increase in margin trading balances, with the electronics sector leading with an increase of 1.450 billion yuan, followed by the defense and military industry and non-ferrous metals, which increased by 0.507 billion yuan and 0.486 billion yuan, respectively [1] Stock Performance - A total of 1,844 stocks experienced an increase in margin trading balances, accounting for 50.10% of the total, with 328 stocks seeing an increase of over 5% [1] - The stock with the largest increase in margin trading balance was Hengyu Xintong, which had a latest margin balance of 45.283 million yuan, reflecting a 116.63% increase, although its stock price fell by 0.12% on the same day [1] - Other notable stocks with significant increases in margin trading balances included Tengya Precision and Juneng Co., with increases of 101.08% and 73.33%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the largest increases in margin trading balances, the average stock price rose by 1.88%, with notable gainers including Taotao Automotive, Jixin Technology, and Xiangyu Medical, which saw increases of 14.71%, 9.98%, and 8.11%, respectively [2] - Conversely, the stocks with the largest declines included Hongyu Packaging, Kelon New Materials, and Tengya Precision, with declines of 5.72%, 4.08%, and 3.91%, respectively [2] Margin Trading Balance Declines - In contrast to the stocks with increased margin trading balances, 1,837 stocks saw a decrease, with 225 stocks experiencing a decline of over 5% [4] - The stock with the largest decrease in margin trading balance was Huawi Design, which saw a decline of 35.29%, bringing its latest margin balance to 5.819 million yuan [4] - Other stocks with significant declines included Minexplosion Optoelectronics and Jibeier, with decreases of 32.37% and 27.68%, respectively [4]

Summary of Xiangyu Medical Conference Call Industry and Company Overview - **Company**: Xiangyu Medical - **Industry**: Medical Technology and Rehabilitation Key Points and Arguments 1. **Core Technology and Market Position**: Xiangyu Medical has been developing brain-computer interface (BCI) technology for nearly a decade, mastering core technologies such as chips and EEG information collection, establishing a unique domestic advantage, and planning to export technology externally [2][3][4] 2. **Product Launch Timeline**: The company expects to launch approximately 24 new BCI rehabilitation products between June and September 2025, with registration certificates anticipated by the end of the year [2][4] 3. **Insurance Policy Support**: Relevant medical insurance charging standards have been established in regions like Hubei (966 RMB per session) and Zhejiang (960 RMB per session), which are expected to promote industry development [2][4][14] 4. **Order Procurement Trends**: There is a recovery trend in order procurement, with expectations for continued growth in the third quarter, as both large hospitals and grassroots medical institutions increase purchases [2][5][6] 5. **Application Areas**: Current BCI products are primarily used for rehabilitation training in neurodegenerative diseases and post-stroke recovery, with future plans to integrate with exoskeleton robots and balance training products [2][7] 6. **Non-invasive Signal Acquisition**: The company’s non-invasive signal acquisition devices utilize self-developed technology, featuring 2 to 512 channels, with industry-leading parameters in signal transmission rate, common-mode rejection ratio, and signal-to-noise ratio [2][10] 7. **AI Model Development**: Xiangyu Medical has launched the VTE intelligent prevention system, achieving a 99% accuracy rate in NLP multi-data analysis and a 45% reduction in missed diagnoses [3][25] 8. **Market Expansion Plans**: The company plans to leverage existing channels and partnerships with research institutions to promote BCI products and develop embedded projects like BCI treatment centers [3][12] 9. **Employee Incentives**: An employee stock ownership plan has been introduced to incentivize R&D and marketing personnel, with specific performance targets set for revenue and registration achievements [13] 10. **Future Product Development**: New BCI products are aimed at conditions such as stroke sequelae, spinal cord injuries, Parkinson's disease, depression, sleep disorders, and autism, with a comprehensive rehabilitation treatment system being developed [19][20] Additional Important Information 1. **Cost Advantages**: Xiangyu Medical has significant cost advantages due to self-developed core algorithms and hardware, allowing for lower pricing compared to foreign competitors [16][17] 2. **Regulatory Environment**: The company anticipates obtaining the BCI registration certificate by the end of December 2025, with a typical approval cycle of around six months [8] 3. **Consumer Market Plans**: Plans for consumer-oriented BCI devices include products for motion sickness, attention monitoring, and sleep assistance, with prototypes expected to be released this year [21] 4. **Exoskeleton Robot Integration**: The integration of BCI with exoskeleton robots is expected to yield prototypes this year, with certification anticipated in 2026 [22] 5. **Technological Maturity**: Key technologies include human-computer interaction, multi-sensor fusion, and autonomous navigation, which are already mature and being applied in various rehabilitation and elderly care scenarios [24] 6. **Future R&D and Marketing Strategy**: The company is increasing its R&D and marketing personnel to support its technology layout, with a focus on traditional channels and training for new product promotion [27][28]

河南翔宇医疗设备股份有限公司 2025 年员工持股计划 证券简称：翔宇医疗 证券代码：688626 河南翔宇医疗设备股份有限公司 2025 年员工持股计划 河南翔宇医疗设备股份有限公司 二〇二五年七月 河南翔宇医疗设备股份有限公司 2025 年员工持股计划 声明 本公司董事会及全体董事保证本员工持股计划不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本员工持股计划主要条款与公司于 2025 年 6 月 13 日披露的《河南翔宇医 疗设备股份有限公司 2025 年员工持股计划（草案）》及其摘要内容一致。 2 河南翔宇医疗设备股份有限公司 2025 年员工持股计划 风险提示 一、有关本员工持股计划的具体资金来源、出资金额、实施方案等属初步结 果，能否完成实施，存在不确定性。 二、若参加对象认购比例较低，本员工持股计划存在不能成立的风险；若参 加对象认购资金不足，本员工持股计划存在低于预计规模的风险。 三、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3 河南翔宇医疗设备股份有限公司 2025 年员工持股计划 特别提示 一、河南翔宇 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-039 （一） 股东大会召开的时间：2025 年 7 月 1 日 （二） 股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 12,912,332 | | 普通股股东所持有表决权数量 | 12,912,332 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 8.3745 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 8.3745 | 河南翔宇医疗设备股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 注：公司表决权数量不 ...

上海市通力律师事务所 关于河南翔宇医疗设备股份有限公司 2025 年第一次临时股东大会的法律意见书 致:河南翔宇医疗设备股份有限公司 上海市通力律师事务所(以下简称"本所")接受河南翔宇医疗设备股份有限公司(以下 简称"公司")的委托,指派本所黄雅程律师、韩宇律师(以下简称"本所律师")根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范 性文件(以下统称"法律法规")及《河南翔宇医疗设备股份有限公司章程》(以下简称"公 司章程")的规定就公司 2025年第一次临时股东大会(以下简称"本次股东大会")相关事 宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].

Market Overview - The Shanghai Composite Index closed at 3444.43 points, above the five-day moving average, with a gain of 0.59% [1] - The total trading volume of A-shares reached 1,517.37 billion yuan [1] Stocks Performance - A total of 664 A-shares have surpassed the five-day moving average, indicating positive momentum [1] - Notable stocks with significant deviation rates include: - Morningstar Airlines (15.14%) - Xiangyu Medical (14.86%) - Qifeng Precision (13.27%) [1][2] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - China Duty Free Group - Shanghai Yizhong - Shanjin International [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Morningstar Airlines: 19.99% increase, 15.14% deviation [2] - Xiangyu Medical: 20.01% increase, 14.86% deviation [2] - Qifeng Precision: 17.25% increase, 13.27% deviation [2] - Other notable stocks include: - Lianjian Optoelectronics: 19.92% increase, 10.74% deviation [2] - Songsheng Co.: 13.73% increase, 10.55% deviation [2]

Market Overview - The A-share market experienced a significant rebound on June 30, with the Shanghai Composite Index rising by 0.59%, the Shenzhen Component Index by 0.83%, and the ChiNext Index by 1.35% [2] - A total of 4,056 companies saw their stock prices increase, while 1,127 companies declined, with 92 stocks hitting the daily limit up [3][4] - In the first half of the year, the Shanghai Composite Index rose by 2.76%, and the North Star 50 Index surged by 39.45%, reaching a historical high [3] Sector Performance - The military industry sector saw a notable surge, with stocks like Great Wall Military Industry and North Navigation hitting the daily limit up. This was influenced by the upcoming grand military parade on September 3, showcasing domestically produced main battle equipment [5] - The brain-computer interface sector also experienced a rise, with stocks such as Xiangyu Medical and Innovation Medical reaching the daily limit up. This was driven by Neuralink's recent developments and future plans for human-machine integration [7][8] Gaming Industry - The gaming sector saw a significant increase following the announcement of 147 domestic game approvals and 11 imported game approvals by the National Press and Publication Administration, marking a record high for monthly approvals in recent years. Major companies like Tencent and NetEase received approvals [9] - Citic Securities expressed optimism about the gaming sector, highlighting that the core companies' valuations are significantly lower than those in the new consumption sector, suggesting potential growth [9] Trade Developments - Positive trade news emerged as Canada lifted its digital services tax on tech companies, aiming to restart negotiations with the U.S. [9] - India's trade team extended its stay in Washington to resolve differences, with hopes of reaching a temporary agreement before the July 9 deadline [10]

截至2025年6月30日 13:30，上证科创板综合指数(000680)强势上涨1.51%，成分股翔宇医疗(688626)上涨 20.01%，华强科技(688151)上涨16.29%，晶品特装(688084)上涨15.29%，毕得医药(688073)，药康生物 (688046)等个股跟涨。科创综指ETF(589680)上涨1.56%，最新价报0.98元。 科创综指ETF(589680)，场外联接A：023757；联接C：023758；联接I：024141。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 民生证券称，AI应用百花齐放，医疗、司法、金融、教育等具备广阔落地潜力。随着国产模型、国产 算力生态成熟，AI应用在多个垂直场景有望加速落地。以医疗为例，6月26日，蚂蚁集团推出全新的AI 健康应用"AQ"。基于蚂蚁的医疗大模型，AQ提供健康科普、就诊咨询、报告解读、健康档案等AI功 能，连接了全国超5000家医院、近百万医生、近200个名医AI分身等医疗服务。阿里、蚂蚁、字节、腾 讯等国内科技巨头纷纷入局，以模型能力为基石，联合拥有深刻行业Know-how的IT厂商，加速推进AI 应 ...